Synta to Participate in FBR Second Annual Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--

Synta Pharmaceuticals Corp. SNTA today announced that the Company will be participating in the FBR Second Annual Healthcare Conference on Wednesday, September 9^th in Boston. There is no formal presentation during the conference, however, management will be available for one-on-one meetings.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. Synta's lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90 inhibitor Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150902006354/en/